Urinary Catalytic Iron in Patients with Type 2 Diabetes without Microalbuminuria—a Substudy of the ACCORD Trial
- 1 February 2011
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 57 (2), 341-344
- https://doi.org/10.1373/clinchem.2010.155887
Abstract
No abstract availableFunding Information
- Novo Nordisk
- Amylin Pharmaceuticals
- Medtronic
- Novartis
- Tolerex
- Osiris Therapeutics
- Halozyme Therapeutics
- Pfizer
- Roche
- Intekrin Therapeutics
- Merck
- Dexcom
- Johnson & Johnson
- Bristol-Myers Squibb
- Fujisawa Pharmaceutical
- NIH
- American Diabetes Association
- Tullis-Tulane Chair in Diabetes
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD043451)
- National Heart Lung and Blood Institute
- Louisiana Board of Regents
This publication has 7 references indexed in Scilit:
- Urinary Catalytic Iron in ObesityClinical Chemistry, 2011
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and MethodsThe American Journal of Cardiology, 2007
- HPLC–Atmospheric Pressure Chemical Ionization MS/MS for Quantification of 15-F2t-Isoprostane in Human Urine and PlasmaClinical Chemistry, 2007
- Oxidants in Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2007
- Role of ‘catalytic’ iron in an animal model of minimal change nephrotic syndromeKidney International, 1996
- EditorialMethods, 1990
- [1] Role of free radicals and catalytic metal ions in human disease: An overviewMethods in Enzymology, 1990